A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Key Inclusion Criteria:

• Diagnosis of moderate to severe facial AV

• Facial IGA) score of 3 (moderate) or 4 (severe)

• At least 20 and no more than 100 inflammatory lesions on the face

• No more than 100 non-inflammatory lesions on the face.

• No more than 5 nodules (≥5 millimeter [mm]) on the face

Key Exclusion Criteria:

• A participant with acne fulminans or conglobate or secondary acne will be excluded.